H eparin has been used in coronary angioplasty procedures since this nonsurgical revascularization technique was first introduced in 1977.1 Intraprocedural use of anticoagulation was empirically deemed necessary because of the direct introduction of thrombogenic wire and catheter equipment into the diseased coronary artery as well as the local activation of coagulation factors and platelets as a consequence of balloon dilatation, plaque compression, and subintimal exposure. Despite the conventional use of intravenous heparin during coronary angioplasty, there is a 6-8% reported rate of abrupt vessel closure2-4 occurring either intraprocedurally or within 24 hours of balloon dilatation, which accounts for most of the initial mortality, emergency coronary bypass surgery, and morbidity of the procedures At least half of these acute closure events are due to coronary artery thrombosis, whereas many may be related to vessel wall laceration or to a combination of both factors.2 Recent retrospective analyses indicate that the rate of thrombotic closure may be diminished by higher doses of heparin with intraprocedural monitoring of its anticoagulant effect.6,7
The major theoretical limitations of heparin are that it cannot inactivate clot-bound thrombin, which proteolytically activates platelets and cleaves fibrinogen, relies on the presence of anti-thrombin III at adequate levels, and is neutralized by components of the platelet release reaction such as platelet factor 4 and heparinase. This results in considerably reduced efficacy of heparin in inhibiting thrombin-induced cyclic flow alterations caused by platelet aggregation and dislodgment at sites of endothelial injury and coronary artery stenosis in experimental models.8 Each of these limitations is potentially overcome by a novel synthetic, bivalent, direct thrombin inhibitor known as hirulog.9,10 These peptides were designed from hirudin, the most potent natural and specific inhibitor of thrombin. In the present multicenter dose escalation study, our objective was to determine the appropriate dose and feasibility of using hirulog as the sole anticoagulant during coronary angioplasty.
Methods

Patient Population
Patients undergoing coronary angioplasty procedures were considered for inclusion into the study if 12 mg of celite and a cylindrical bar magnet. The test tube was vigorously shaken 10 times and was placed in the instrument's incubated test well, which has a magnet detector at its base. The temperature was maintained at 37°C by the incubator. The timer was activated by an audible tone when a fibrin mass formed, causing the magnet to rotate with the tube; the digital readouts were in seconds and were recorded. Because of the variability of sources of measurement at the 11 participating sites and different methods at individual sites (bedside versus central laboratory), the maximum value during the 4-hour infusion (however it was measured) was used for the analysis. aPTT ratios were calculated using the patient's baseline value as the nasal, retroperitoneal, urinary tract, menstrual). Mild bleeding was defined as <250 mL observed blood loss and c1 g/dL decline in hemoglobin; moderate bleeding signified >250 mL observed blood loss and >2 g/dL fall in hemoglobin; severe bleeding was defined as requiring transfusion, resulting in hemodynamic instability, or intracranial hemorrhage.
Pharmacokinetics
For determination of plasma levels of hirulog, blood samples were drawn at baseline, when the angioplasty was complete, at the end of dosing, 2 hours after the end of dosing, and at 24 hours. Because the duration of angioplasty varied from patient to patient, for purposes of analysis, hirulog serum level data have been grouped at the median duration at 0.5 hours. Hirulog was quantitated by an inhibitory enzyme immunoassay that detects the peptide via its ability to inhibit the binding of a highly specific murine antihirulog antibody. laboratory variable was assessed; none of these three patients had primarily thrombotic occlusions. There were two deaths in the study. Both occurred in the 1.0 mg * kg`-l hr-' dose group (group 2). One patient did not have a successful angioplasty because the guide wire could not be passed across the stenosis, which was totally occluded. Hirulog was discontinued 1.25 hours later, and the patient was maintained on heparin. On the following morning, the patient suffered a myocardial infarction, later developed bradycardia and asystole, and died. The other death occurred after a two-vessel angioplasty procedure complicated by thrombus in one vessel and dissection in the other. The patient developed a myocardial infarction, ventricular tachyarrhythmias, and died 1 hour after discontinuation of the study drug. This death was attributed to an abrupt vessel closure.
In Table 3 , the results of abrupt vessel closure are compared for the different dose groups. By intention to treat, the events for dose groups 1-3 were 11.3% compared with 3.9% for groups 4 '20 It is unclear whether some prolongation of the aPTT or ACT in response to hirulog or heparin also represents the same level of anticoagulation and antithrombotic protection. Of note, however, the current study suggests that only when the median ACT values approach or exceed 300 seconds is there a marked reduction in the incidence of abrupt closure.
Previous Work With Hirulog
Using hirudin as a model, Maraganore et al10 designed the novel class of dodecapeptides known as hirulogs. Hirulog is bivalent; it combines the D-Phe-ProArg catalytic site antithrombin and the C-terminal portion of hirudin (residues 53-64) that binds the anion exosite of thrombin with a polyglycyl linker. Previous studies have demonstrated the high in vitro potency of hirulog.10 Hirulog has been shown to be effective in inactivating clot-bound thrombin, which is resistant to heparin.2' In vivo, the bifunctional antithrombin peptide markedly attenuated thrombus formation onto segments of endarterectomized aorta in a baboon experimental model. 22 In phase 1 studies with normal volunteers, hirulog at a dose of 0.3 mg *kg-' hr-' prolonged the aPTT more than twice baseline values, was unaffected by aspirin, and was not associated with 
Study Limitations
The present study is limited by having no control group of heparin-treated patients for a more meaningful comparison of abrupt closure events. However, the dose escalation study was necessary to determine what level of hirulog dosing was necessary to inhibit coronary thrombotic events and whether the drug would be tolerated in this setting of invasive vascular sheaths, concomitant use of aspirin, and the possibility of requiring emergency coronary bypass surgery. Historical controls from multiple recent series2-4 indicate that even with intravenous heparin, there is an appreciable (6-8%) and clinically important rate of abrupt vessel closure. Whether this can be significantly reduced using very-high-dose heparin and in-laboratory anticoagulation ACT monitoring or with the newer direct thrombin inhibitors remains to be determined in larger, controlled studies.
In the study, we did not have standardized laboratory determinations of aPTTs throughout the 11-site network. While this would have lessened the variability in the anticoagulation parameter, this problem is representative of the field, i.e., there are a number of methods to assess the status of anticoagulation and, unfortunately, no uniform standards or recommendations have been established during coronary angioplasty. On the other hand, the method for determining ACTs in the trial was fixed throughout the multicenter network and there was concordance in the hirulog dose response between aPTT and ACT (Figures 1 and 2 ).
Below hirulog dose levels of 1.0 mg . kg`* hr-1, there was a poor correlation between aPTT and ACT.
Conclusions
The present study documents for the first time that it is possible to perform coronary angioplasty in patients pretreated with aspirin using an anticoagulant other than heparin. The use of hirulog was associated with a rapid-onset, dose-dependent anticoagulant effect, minimal bleeding complications, and at doses of 1.8-2.2 mg/kg, a significant reduction of abrupt vessel closure to <4%. With only historical controls from other studies of abrupt vessel closure,2-4 it is difficult to assess the significance of this absolute frequency of closure events. Our findings suggest that a large-scale randomized trial comparing the direct thrombin inhibitor hirulog with heparin is warranted.
